Follow The Filings

ORIC Oric Pharmaceuticals Inc.

Health Care, filed as ORIC PHARMACEUTICALS INC (COM), Equity As of 2026 Q2 among managers we track Quote on Google Finance, opens in a new tab

Sold by 2 managers in 2026 Q2

  • 1 Owner
  • Max 0.2%
  • $56M
  • 1 reduce 1 exit

In 2026 Q2 Andreas Halvorsen trimmed Oric Pharmaceuticals, and Nathan Fischel sold out.

Who owns this now

Largest portfolio weights among holders, up to 0.2% (Andreas Halvorsen, Viking Global Investors). Not free-float ownership.

  1. Andreas Halvorsen Reduce 0.16%

Who owns ORIC

Sorted by value, long equity only, as of 2026 Q2.

History
Andreas Halvorsen, Viking Global Investors 0.16%, was 0.21% Reduce −12.0% 5,126,762 $56M History
Nathan Fischel, Dafna Capital Management exited 2026 Q2 Last 2026 Q1 0.22% Exit −0.22% 98,724 $945K History

Weight bar: held both quarters added sold at this quarter’s reported price

Insider trades

Open-market buys and sales by ORIC's executives, directors and 10% owners in the last 12 months, from their Form 4s

All ORIC insider trades
  • None no insider bought on the open market
  • None no sales outside a trading plan
  • $2.5M sold by 2 insiders under 10b5-1 plans
  1. Dominic Piscitelli CFO
    Planned sale
    $189K 14,000 shares at $13.53 17% of stake
    Traded Oct 20 Filed Oct 21
  2. Richard A. Heyman Director
    Planned sale
    $87K 6,700 shares at $12.91
    Traded Oct 1 Filed Oct 2
  3. Dominic Piscitelli CFO
    Planned sale
    $181K 13,400 shares at $13.53 16% of stake
    Traded Sep 28 Filed Sep 29
  4. Dominic Piscitelli CFO
    Planned sale
    $8,103 600 shares at $13.50 0.9% of stake
    Traded Sep 24 Filed Sep 25
  5. Dominic Piscitelli CFO
    Planned sale
    $1.1M 77,000 shares at $13.69 52% of stake
    Traded Aug 26 Filed Aug 28
  6. Richard A. Heyman Director
    Planned sale
    $157K 13,100 shares at $12.02
    Traded Jul 24 Filed Jul 28
  7. Richard A. Heyman Director
    Planned sale
    $3,600 300 shares at $12.00 0.1% of stake
    Traded Jul 6 Filed Jul 8
  8. Dominic Piscitelli CFO
    Planned sale
    $703K 52,000 shares at $13.51 43% of stake
    Traded Feb 24 Filed Feb 26
  9. Richard A. Heyman Director
    Planned sale
    $80K 6,700 shares at $12.00
    Traded Jan 16 Filed Jan 20

Also filed in the last 12 months, not counted as buying or selling: 13 option exercises and 3 sales to cover taxes.

SEC filings

Recent issuer filings from EDGAR, 20 shown.

Filed Form Detail Links
8-K 2.02,9.01
10-Q
8-K 5.02,9.01
8-K 5.02,5.07,9.01
SCHEDULE 13G —
SCHEDULE 13G/A —
SCHEDULE 13G/A —
SCHEDULE 13G/A —
SCHEDULE 13G/A —
8-K 2.02,9.01
10-Q
DEF 14A
DEFA14A
8-K 8.01,9.01
8-K 2.02,9.01
10-K
424B5
8-K 8.01,9.01
SCHEDULE 13G/A —
SCHEDULE 13G —

Financials

US-GAAP annual figures by fiscal year, as tagged in Form 10-K. Each value links to its SEC filing.

Income statement

Metric FY2023 FY2024 FY2025
Net income -$100.7M -$127.85M -$129.47M

Balance sheet

Metric FY2023 FY2024 FY2025
Total current assets $212.6M $262.25M $288.47M
Total non-current assets * $39.41M $11.89M $120.42M
Total assets $252.01M $274.14M $408.89M
Total current liabilities $20.46M $24.85M $20.42M
Total non-current liabilities * $7.46M $6.17M $4.11M
Total equity $224.09M $243.12M $384.36M

Cash flow

Metric FY2023 FY2024 FY2025
Cash from operations -$85.69M -$112.66M -$110.97M
Cash from investing -$43.4M $22.14M -$148.03M
Cash from financing $85.66M $126.55M $245.26M
Net change in cash -$43.43M $36.02M -$13.74M

Ownership over time

13Fs that reported it each quarter. Click a bar for that quarter’s holders.